Kadori Marshall
Psychiatric/Mental Health · Dublin, OHNPI 1649882200
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (58.5%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) accounts for 86.2% of it on its own, with 9 other manufacturers making up the rest. 2025 is the largest year on record at $18,050, more than ten times the $895 reported in 2021. Among psychiatric/mental health clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 85 payments — averaging $246.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$18K
- Teva Pharmaceuticals USA, Inc.$1K
- AbbVie$562
- Axsome Therapeutics, Inc.$433
- Neurocrine Biosciences, Inc.$250
- Otsuka America Pharmaceutical, Inc.$233
- plus $342 from 4 others
What the payments were for
- Consulting fees$3,18815%
- Speaking & faculty fees$12,24058%
- Travel & lodging$8774%
- Food & beverage$4,35721%
- Education$2701%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 34 | $18,040 |
| Teva Pharmaceuticals USA, Inc. | 12 | $1,071 |
| AbbVie(2 entities) | 26 | $562 |
| Axsome Therapeutics, Inc. | 4 | $433 |
| Neurocrine Biosciences, Inc. | 2 | $250 |
| Otsuka America Pharmaceutical, Inc. | 2 | $233 |
| E.r. Squibb & Sons, L.L.C. | 1 | $111 |
| Alkermes, Inc. | 1 | $100 |
| Alpha Cognition USA, Inc. | 2 | $77 |
| Supernus Pharmaceuticals, Inc. | 1 | $54 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$20,931 in reported general payments places this provider in the 95th percentile of 1,808 psychiatric/mental health providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CaplytaLumateperone Tosylate | 94 | $161,525 |
| AuvelityDextromethorphan Hbr/Bupropion | 62 | $43,364 |
| Abilify MaintenaAripiprazole | 11 | $31,621 |
| RexultiBrexpiprazole | 18 | $25,429 |
| VraylarCariprazine Hcl | 14 | $20,000 |
| TrintellixVortioxetine Hydrobromide | 25 | $15,030 |
| Aripiprazole | 29 | $6,745 |
| Lurasidone Hcl | 19 | $5,017 |
| Vilazodone Hcl | 22 | $4,586 |
| Ziprasidone Hcl | 26 | $2,037 |
| Oxcarbazepine | 70 | $1,751 |
| Fluvoxamine Maleate ErFluvoxamine Maleate | 12 | $1,369 |
| Paliperidone ErPaliperidone | 15 | $1,279 |
| Duloxetine Hcl | 62 | $1,103 |
| Prazosin Hcl | 35 | $870 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $18,040 | $161,52594 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $233 | $57,05029 claims |
| Axsome Therapeutics, Inc.Auvelity | $433 | $43,36462 claims |
| AbbVieVraylar | $562 | $20,00014 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,808 psychiatric/mental health providers in Ohio.
Other psychiatric/mental health in Dublin
- Crystal TravisJackson$333K
- Kristina RoweIronton$253K
- Patricia SparksPortsmouth$210K
- Mary HallWarren$195K
- Kassandra KornbauCanfield$170K
- Steven MatesDayton$121K
- Robert ParsonsYoungstown$119K
- Chriscia BaneChillicothe$115K
- Rachael McLaughlinMaple Heights$114K
- Danielle MorroneCanfield$94K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.